With a total revenue of nearly $2.7 billion, Vertex exceeded analyst estimates in the first quarter, bolstered by strong uptake of its cystic fibrosis products.
Tag Archive for: cystic fibrosis
Sionna Therapeutics announced it raised another round of funding as the company looks to challenge Vertex Pharmaceuticals’ dominant cystic fibrosis business.
The company’s three-drug combination met all primary and key secondary endpoints in two randomized controlled trials in cystic fibrosis patients, paving the way for an application to regulators.
Bringing in an additional $50 million in a Series B extension, ReCode Therapeutics’ total haul for the funding round totaled $260 million, which it will use to further its experimental mRNA therapies.
The biopharma company reported sales of $2.24 billion in the second quarter for the cystic fibrosis treatment, beating analysts’ estimate, after it won FDA approval in children ages two to five in April.
Messenger RNA (mRNA)-based therapeutics have seen a boom in popularity in recent years, a space that has become increasingly competitive as pharma giants entered to produce COVID-19 vaccines and therapies that target a wider range of diseases.
A look at factors associated with Alzheimer’s disease; how antisense oligonucleotides could create a protein missing in cystic fibrosis patients; how belly fat increases the risk of metabolic disease; and how COVID booster shots offset some of the variants’ immune evasion tactics.